CD8A and acute respiratory distress syndrome: A candidate drug should meet the requirements to (1) inhibit SARS-CoV replication, (2) enhance CD8+ mediated adaptive immunity, (3) depress cytokine storm, and (4) promote autophagy-dependent protective mechanism to ameliorate ALI.